News|Videos|August 31, 2026
Regulatory Roundup—August 2026
Author(s)Susan Haigney
In August 2026, Heidi Overton was nominated for FDA commission, and a wave of oncology and neuro drugs were approved.
Advertisement
Advertisement
In August 2026, a new FDA commissioner was nominated by the White House; there was a variety of novel drug approvals spanning oncology to narcolepsy; and parallel moves from the United Kingdom's MHRA and Europe's EDQM were made to modernize standards—all set against tightened manufacturing scrutiny on both sides of the Atlantic.
Advertisement
Advertisement